Michael J Schell

Summary

Affiliation: H. Lee Moffitt Cancer Center and Research Institute
Country: USA

Publications

  1. ncbi request reprint Evidence-based target recall rates for screening mammography
    Michael J Schell
    Biostatistics Division, Department of Interdisciplinary Oncology, Moffitt Research Center, 12902 Magnolia Dr, Tampa, FL 33612 9497, USA
    Radiology 243:681-9. 2007
  2. doi request reprint Thymidylate synthase in situ protein expression and survival in stage I nonsmall-cell lung cancer
    Zhong Zheng
    Program and Division of Thoracic Oncology, H Lee Moffitt Cancer Center and Research Institute, Tampa, Florida 33612 9497, USA
    Cancer 112:2765-73. 2008
  3. pmc Features of potentially predictive biomarkers of chemotherapeutic efficacy in small cell lung cancer
    Alberto A Chiappori
    Thoracic Oncology Program, H Lee Moffitt Cancer Center and Research Institute, Tampa, Florida 33612, USA
    J Thorac Oncol 5:484-90. 2010
  4. pmc Analysis of group randomized trials with multiple binary endpoints and small number of groups
    Ji Hyun Lee
    Biostatistics Core, H Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States of America
    PLoS ONE 4:e7265. 2009
  5. pmc A predictive risk probability approach for microarray data with survival as an endpoint
    Dung Tsa Chen
    Biostatistics Division, Moffitt Cancer Center and Research Institute, University of South Florida, Tampa, Florida 33612, USA
    J Biopharm Stat 18:841-52. 2008
  6. doi request reprint Phase 2 trial of docetaxel and gefitinib in the first-line treatment of patients with advanced nonsmall-cell lung cancer (NSCLC) who are 70 years of age or older
    George R Simon
    Thoracic Oncology Program, H Lee Moffitt Cancer Center and Research Institute, Tampa, FL 33612, USA
    Cancer 112:2021-9. 2008
  7. pmc Phase I/II study of the Src inhibitor dasatinib in combination with erlotinib in advanced non-small-cell lung cancer
    Eric B Haura
    Department of Thoracic Oncology and Biostatistics, Clinical Trials and Clinical Pharmacology Core, H Lee Moffitt Cancer Center and Research Institute, Tampa, FL 33612 9497, USA
    J Clin Oncol 28:1387-94. 2010
  8. doi request reprint Outcomes of adrenalectomy for isolated synchronous versus metachronous adrenal metastases in non-small-cell lung cancer: a systematic review and pooled analysis
    Tawee Tanvetyanon
    Biostatistics Division, H Lee Moffitt Cancer Center and Research Institute, University of South Florida, 12902 Magnolia Dr, Tampa, FL 33613, USA
    J Clin Oncol 26:1142-7. 2008
  9. ncbi request reprint Mirk/Dyrk1B, a novel therapeutic target, mediates cell survival in non-small cell lung cancer cells
    Jingchun Gao
    Department of Experimental Therapeutics and Thoracic Oncology Program, H Lee Moffitt Cancer Center and Research Institute, 12902 Magnolia Drive, Tampa, FL 33612 9497, USA
    Cancer Biol Ther 8:1671-9. 2009
  10. pmc ABCG2 expression, function, and promoter methylation in human multiple myeloma
    Joel G Turner
    H Lee Moffitt Cancer Center and Research Institute, 12902 Magnolia Dr, Tampa, FL 33612, USA
    Blood 108:3881-9. 2006

Detail Information

Publications19

  1. ncbi request reprint Evidence-based target recall rates for screening mammography
    Michael J Schell
    Biostatistics Division, Department of Interdisciplinary Oncology, Moffitt Research Center, 12902 Magnolia Dr, Tampa, FL 33612 9497, USA
    Radiology 243:681-9. 2007
    ..To retrospectively identify target recall rates for screening mammography on the basis of how sensitivity shifts with recall rate...
  2. doi request reprint Thymidylate synthase in situ protein expression and survival in stage I nonsmall-cell lung cancer
    Zhong Zheng
    Program and Division of Thoracic Oncology, H Lee Moffitt Cancer Center and Research Institute, Tampa, Florida 33612 9497, USA
    Cancer 112:2765-73. 2008
    ..We hypothesized that intratumoral TS expression would be prognostic of outcome in stage I NSCLC...
  3. pmc Features of potentially predictive biomarkers of chemotherapeutic efficacy in small cell lung cancer
    Alberto A Chiappori
    Thoracic Oncology Program, H Lee Moffitt Cancer Center and Research Institute, Tampa, Florida 33612, USA
    J Thorac Oncol 5:484-90. 2010
    ..Our aim was to determine the expression levels of these proteins to assess their potential clinical utility in SCLC...
  4. pmc Analysis of group randomized trials with multiple binary endpoints and small number of groups
    Ji Hyun Lee
    Biostatistics Core, H Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States of America
    PLoS ONE 4:e7265. 2009
    ..The multiple endpoints from the GRT design are analyzed using a generalized linear mixed model and the stepdown Bonferroni method of Holm...
  5. pmc A predictive risk probability approach for microarray data with survival as an endpoint
    Dung Tsa Chen
    Biostatistics Division, Moffitt Cancer Center and Research Institute, University of South Florida, Tampa, Florida 33612, USA
    J Biopharm Stat 18:841-52. 2008
    ..Third, analysis of resampling the risk probability suggested the variation pattern of the log-rank chi(2) in the colon cancer data set was unlikely caused by chance...
  6. doi request reprint Phase 2 trial of docetaxel and gefitinib in the first-line treatment of patients with advanced nonsmall-cell lung cancer (NSCLC) who are 70 years of age or older
    George R Simon
    Thoracic Oncology Program, H Lee Moffitt Cancer Center and Research Institute, Tampa, FL 33612, USA
    Cancer 112:2021-9. 2008
    ..The primary endpoint was response rate (RR). Secondary endpoints were overall survival (OS) and progression-free survival (PFS)...
  7. pmc Phase I/II study of the Src inhibitor dasatinib in combination with erlotinib in advanced non-small-cell lung cancer
    Eric B Haura
    Department of Thoracic Oncology and Biostatistics, Clinical Trials and Clinical Pharmacology Core, H Lee Moffitt Cancer Center and Research Institute, Tampa, FL 33612 9497, USA
    J Clin Oncol 28:1387-94. 2010
    ....
  8. doi request reprint Outcomes of adrenalectomy for isolated synchronous versus metachronous adrenal metastases in non-small-cell lung cancer: a systematic review and pooled analysis
    Tawee Tanvetyanon
    Biostatistics Division, H Lee Moffitt Cancer Center and Research Institute, University of South Florida, 12902 Magnolia Dr, Tampa, FL 33613, USA
    J Clin Oncol 26:1142-7. 2008
    ..However, some suggest that the survival outcome among patients with a synchronous metastasis is poor. It remains unclear whether this treatment approach is warranted among those with synchronous metastasis...
  9. ncbi request reprint Mirk/Dyrk1B, a novel therapeutic target, mediates cell survival in non-small cell lung cancer cells
    Jingchun Gao
    Department of Experimental Therapeutics and Thoracic Oncology Program, H Lee Moffitt Cancer Center and Research Institute, 12902 Magnolia Drive, Tampa, FL 33612 9497, USA
    Cancer Biol Ther 8:1671-9. 2009
    ..These results suggest that Mirk is overexpressed in lung cancer, acts as a survival factor in lung cancer cells and may be a novel therapeutic target...
  10. pmc ABCG2 expression, function, and promoter methylation in human multiple myeloma
    Joel G Turner
    H Lee Moffitt Cancer Center and Research Institute, 12902 Magnolia Dr, Tampa, FL 33612, USA
    Blood 108:3881-9. 2006
    ..These findings suggest that ABCG2 is expressed and functional in human myeloma cells, regulated by promoter methylation, affected by cell density, up-regulated in response to chemotherapy, and may contribute to intrinsic drug resistance...
  11. pmc Deregulation of IKBKE is associated with tumor progression, poor prognosis, and cisplatin resistance in ovarian cancer
    Jian Ping Guo
    Departments of Molecular Oncology, H Lee Moffitt Cancer Center, Tampa, Florida 33612, USA
    Am J Pathol 175:324-33. 2009
    ..IKKepsilon could also serve as a prognostic marker and potential therapeutic target for this malignancy...
  12. ncbi request reprint Second-line, low-dose, weekly paclitaxel in patients with stage IIIB/IV nonsmall cell lung carcinoma who fail first-line chemotherapy with carboplatin plus paclitaxel
    Mark A Socinski
    Multidisciplinary Thoracic Oncology Program, Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, 27599, USA
    Cancer 95:1265-73. 2002
    ..The authors sought to determine the activity of second-line, low-dose, weekly paclitaxel in patients with NSCLC who failed first-line chemotherapy with carboplatin plus paclitaxel...
  13. ncbi request reprint The impact of age on toxicity, response rate, quality of life, and survival in patients with advanced, Stage IIIB or IV nonsmall cell lung carcinoma treated with carboplatin and paclitaxel
    Thomas A Hensing
    Multidisciplinary Thoracic Oncology Program, Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, North Carolina, USA
    Cancer 98:779-88. 2003
    ....
  14. ncbi request reprint Recall and detection rates in screening mammography
    Bonnie C Yankaskas
    Cancer 101:2710-1; author reply 2711-2. 2004
  15. ncbi request reprint Factors associated with the likelihood of receiving second line therapy for advanced non-small cell lung cancer
    Thomas A Hensing
    Thoracic Oncology Program, Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC, USA
    Lung Cancer 47:253-9. 2005
    ..Factors increasing the likelihood of second-line therapy include high performance status, female gender and non-squamous histology, while early termination of first-line therapy decreased the likelihood of further therapy...
  16. ncbi request reprint Comparison of three methods to increase knowledge about breast cancer and breast cancer screening in screening mammography patients
    Dag Pavic
    Department of Radiology, University of North Carolina at Chapel Hill, CB 7510, Chapel Hill, NC 27599 7510, USA
    Acad Radiol 14:553-60. 2007
    ..The specific aim of the study was to determine which of several cost-effective interventions is best able to improve the breast cancer knowledge of women who present for screening mammography...
  17. ncbi request reprint Phase III trial comparing a defined duration of therapy versus continuous therapy followed by second-line therapy in advanced-stage IIIB/IV non-small-cell lung cancer
    Mark A Socinski
    Multidisciplinary Thoracic Oncology Program, Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC 27599, USA
    J Clin Oncol 20:1335-43. 2002
    ..To compare four cycles of therapy versus continuous therapy to determine the optimal duration of chemotherapy in advanced non-small-cell lung cancer (NSCLC)...
  18. ncbi request reprint Carboplatin-based chemotherapy in patients with advanced non-small cell lung cancer and a poor performance status
    Thomas E Stinchcombe
    Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, 27599, USA
    Lung Cancer 51:237-43. 2006
    ....
  19. ncbi request reprint Factors predicting successful needle-localized breast biopsy
    Page E Abrahamson
    Department of Epidemiology, Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC 27599, USA
    Acad Radiol 10:601-6. 2003
    ..The purpose of this study was to identify factors that predict successful removal of nonpalpable breast lesions with mammography-guided needle-localized breast biopsy...